Beginning in the late 1990s, Biovest International’s primary focus was the commercialization of personalized immunotherapies. In 2013, Biovest International, Inc. emerged from its parent company, Accentia Biopharmaceuticals. By this time, Biovest had developed an active immunotherapy to treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma. The Company’s lead personalized cancer vaccine product candidate, BiovaxID™, was evaluated in three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) demonstrating that BiovaxID increases the duration of cancer remission following chemotherapy and induces immune responses which correlate highly with long-term survival. Despite showing promise in clinical trials, BiovaxID faced regulatory hurdles and did not receive marketing authorization in Europe. The company also developed innovative cell culture and bioreactor systems, holding several patents in these areas.
In 2016, Biovest International, Inc. announced the spin off of its instrument and contract manufacturing offerings into Cell Culture Company, LLC. Cell Culture Company supplies automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services. So far, customers are served globally in the diagnostic, therapeutic, and animal healthcare industries. The spin-off of Cell Culture Company ensured that instrument and CMO customers were better served through increased focus and investment. Cell Culture Company, LLC is a wholly-owned subsidiary of Biovest International, Inc.
For additional information, contact us.
